Objective
Regenerative Medicine (use of cells and tissue to replace or heal impaired functions in the body, RM) is one of the fastest growing areas in today’s medicine, and has the potential to offer treatment to patients with diseases that are currently untreatable. In many new areas of RM there is however a need to improve the outcome of RM concepts and technologies for it to become a viable option to traditional medicine, or even to motivate the risk of clinical trials and treatments. One of the main problems in several RM areas is that a large portion of the cell and tissue material is lost or made dysfunctional during and shortly after transplantation and that the transplant does not connect to the host tissue as a functional new graft. The specific scientific objective of this project is twofold: 1) to clinically test and prove that Corline Heparin Surfaces (CHS) can be used to protect donated human insulin producing cells that are transplanted to severe cases of Diabetes Type 1 patients, and 2) to broaden the application of the technology and show that the CHS technology can function as a protective and revascularization promoting technology for other Regenerative Medicine areas. The goal is to show CHS’s further applicability to Liver Cell therapy, Xeno transplantation of Islet of Langerhans and to Tissue Engineering In addition to the detailed scientific objective, this project has a specific technological objective. The technological objective of this project is to, in partnerships with the participating SMEs, improve European top grade clinical Regenerative Medicine products by combining them with the CHS technology, transferring the application knowledge and integrating the CHS technology into the partners’ cell and tissue production processes, and to set up a reliable sourcing chain with supply and production of reagents and tissue products to end-user.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine integrative and complementary medicine
- medical and health sciences medical biotechnology tissue engineering
- medical and health sciences clinical medicine endocrinology diabetes
- medical and health sciences clinical medicine transplantation
- medical and health sciences medical biotechnology cells technologies
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-SME-2010-1
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
131 46 NACKA
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.